Lixoft operates in the pharmaceutical and biotechnology sectors, providing advanced modeling and simulation software solutions. The company's core product, the Monolix Suite, is designed for pharmacometricians and biostatisticians to streamline drug development processes. Lixoft's tools, such as Mlxplore and Datxplore, offer intuitive and interactive interfaces for exploring and visualizing pharmacokinetic (PK) and pharmacodynamic (PD) models. These products help users save time and energy by simplifying complex statistical analyses and facilitating real-time dose regimen exploration. Lixoft maintains a close research partnership with Inria, ensuring rapid technology transfer from academic research to industry-grade software. The company generates revenue through software licensing and training workshops, serving clients in the pharmaceutical, biotechnology, and academic sectors. Lixoft's business model focuses on continuous innovation and user-friendly solutions to break down barriers in modeling and simulation, promoting collaboration across all stages of drug development.

Keywords: pharmacometrics, biostatistics, drug development, modeling, simulation, Monolix Suite, Mlxplore, Datxplore, Inria partnership, software licensing.